Esperion Therapeutics, Inc. (ESPR) Stake Held by Meditor Group Ltd
Meditor Group Ltd
disclosed that they own a 8.2% stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, August 21st. The investor owns 2,103,200 shares of the stock worth $94,097,168. The disclosure is available through the SEC website at this hyperlink.
Meditor Group Ltd
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Other large investors also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in shares of Esperion Therapeutics during the first quarter worth $158,000. C WorldWide Group Holding A S acquired a new stake in shares of Esperion Therapeutics during the first quarter worth $162,000. Princeton Alpha Management LP acquired a new stake in shares of Esperion Therapeutics during the first quarter worth $205,000. Tower Research Capital LLC TRC increased its stake in shares of Esperion Therapeutics by 69,371.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 4,856 shares during the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the last quarter. 85.39% of the stock is owned by institutional investors and hedge funds.
Esperion Therapeutics, Inc. (NASDAQ ESPR) traded down 2.08% during midday trading on Monday, hitting $43.81. The stock had a trading volume of 414,434 shares. The firm has a 50-day moving average price of $47.33 and a 200-day moving average price of $36.54. The firm’s market capitalization is $989.80 million. Esperion Therapeutics, Inc. has a 1-year low of $9.40 and a 1-year high of $57.38.
Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by $0.25. During the same period in the previous year, the firm posted ($0.62) earnings per share. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post ($7.39) earnings per share for the current year.
A number of analysts have commented on the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $85.00 target price on shares of Esperion Therapeutics in a report on Monday. Bank of America Corporation reiterated a “neutral” rating and issued a $60.00 target price on shares of Esperion Therapeutics in a report on Friday, August 11th. Zacks Investment Research downgraded Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Stifel Nicolaus reiterated a “buy” rating and issued a $70.00 target price (up previously from $60.00) on shares of Esperion Therapeutics in a report on Thursday, August 10th. Finally, Deutsche Bank AG set a $64.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $44.65.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.